Alejandro Olivares-Hernández, Elísabet González Del Portillo, Álvaro Tamayo-Velasco, Luis Figuero-Pérez, Svetlana Zhilina-Zhilina, Emilio Fonseca-Sánchez, José Pablo Miramontes-González
BACKGROUND: The introduction of immunotherapy in the treatment of non-small cell lung cancer (NSCLC) has resulted in a radical change in patients' treatment responses and survival rates. The increased percentage of long survivors, improved toxicity profiles compared to chemotherapy, and the possible applications for different NSCLC scenarios, have led to immune checkpoint inhibitors (ICIs) becoming the cornerstone of NSCLC treatment. Therefore, the objective of this review is to describe the current and future perspectives of NSCLC treatment...
August 30, 2023: Annals of Translational Medicine